On the other hands, multiple lines of evidence support an antitumor immunity by crosstalk of cytokines such as IFN-γ and PD-L1 in the tumor microenvironment, which allows cancers to resist the effects of endogenous tumor-specific T cells [40, 41]. The gene discussed is IFNG; the disease is neoplasm.